NEWSROOM

Press Releases

In the News

Logo & Resources Library

Recent News

Saphnelo™ Approved as Self-Administered Autoinjector

The U.S. Food and Drug Administration just granted approval for a self-administered, once-weekly autoinjector of Saphenlo (anifrolumab), for the treatment of adult patients...

Lupus & Life: Heart Health, Lupus, and How You Can Take Control

How does lupus impact heart health? People living with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular disease, with even...

FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE

The U.S. Food and Drug Administration has accepted the supplemental Biologics License Application from Genentech for Gazyva® (obinutuzumab) to treat systemic lupus erythematosus (SLE), the most common form of...

New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, welcomes new results from the Phase 2 part of the...

Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management

Living with lupus means managing physical symptoms, emotional ups and downs, and the everyday challenges that come with an autoimmune...

New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease activity...

Lupus Research Alliance Applauds U.S. FDA Fast Track Designation for Nipocalimab for Systemic Lupus Erythematosus

Decision Could Help Potential SLE Treatment Reach People Living With Lupus Sooner Decision Could Help Potential SLE Treatment...

Lupus Therapeutics, the Clinical Affiliate of the Lupus Research Alliance, Broadens Proven Peer-to-Peer Program in Clinical Trials

February 24, 2026

New Centralized Model to Include Hundreds of Research Sites Across North America Today, Lupus Therapeutics, the clinical affiliate of the...

Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus

January 28, 2026

Decision Could Speed Up Treatment Approval for Skin-Related Lupus Manifestation The Lupus Research Alliance applauds the decision by the U.S. Food and Drug...

Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care

December 16, 2025

People living with lupus can have early access to innovative therapies alongside personalized support from a broader care team. How?...

Lupus Clinical Research: A New Wave of Innovation

November 6, 2025

A wave of lupus clinical research advances has been building over the past decade. Now, it is reaching a crest. A 2025...

Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025

New York, N.Y., October 21, 2025 — 4 original posters to be presented on cell therapy, patient-reported outcomes, innovative recruitment strategies, and clinical...